Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Insulet Surges After FDA Clears Automated Insulin Delivery Product

Published 28/01/2022, 18:34
Updated 28/01/2022, 18:34
© Reuters.

© Reuters.

By Sam Boughedda

Investing.com — Shares of insulin pump technology firm Insulet Corporation (NASDAQ:PODD) surged more than 15% Friday after it said the U.S. Food and Drug Administration has cleared its Omnipod 5 Automated Insulin Delivery System for type 1 diabetics age six and older.

The Omnipod 5 is said to be the first tubeless automated insulin delivery system that works with the Dexcom (NASDAQ:DXCM) G6 continuous blood glucose monitoring system and a smartphone to automatically adjust insulin according to the user's need to protect against highs and lows.

The product is designed so that users no longer have to take daily insulin injections and take regular blood glucose tests. Currently, type 1 diabetics either have an insulin pump that administers insulin via a tube or take injections around four or five times a day. 

The Omnipod 5 represents Insulet's first foray into the automated insulin dosing market.

"Omnipod 5 is a life-changing technology that we believe will revolutionize the market and the lives of people with diabetes," said Shacey Petrovic, president and CEO of Insulet.

Piper Sandler analysts said the announcement is a "clear positive" for Insulet after previous delays in getting the product cleared. 

However, Piper expects the revenue impact in 2022 will be somewhat muted as the product will roll out slowly.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.